» Articles » PMID: 37894470

Cell Membrane Sialome: Sialic Acids As Therapeutic Targets and Regulators of Drug Resistance in Human Cancer Management

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Oct 28
PMID 37894470
Authors
Affiliations
Soon will be listed here.
Abstract

A cellular sialome is a physiologically active and dynamically changing component of the cell membrane. Sialylation plays a crucial role in tumor progression, and alterations in cellular sialylation patterns have been described as modulators of chemotherapy effectiveness. However, the precise mechanisms through which altered sialylation contributes to drug resistance in cancer are not yet fully understood. This review focuses on the intricate interplay between sialylation and cancer treatment. It presents the role of sialic acids in modulating cell-cell interactions, the extracellular matrix (ECM), and the immunosuppressive processes within the context of cancer. The issue of drug resistance is also discussed, and the mechanisms that involve transporters, the tumor microenvironment, and metabolism are analyzed. The review explores drugs and therapeutic approaches that may induce modifications in sialylation processes with a primary focus on their impact on sialyltransferases or sialidases. Despite advancements in cellular glycobiology and glycoengineering, an interdisciplinary effort is required to decipher and comprehend the biological characteristics and consequences of altered sialylation. Additionally, understanding the modulatory role of sialoglycans in drug sensitivity is crucial to applying this knowledge in clinical practice for the benefit of cancer patients.

Citing Articles

Insights on the Role of Sialic Acids in Acute Lymphoblastic Leukemia in Children.

Radu K, Baek K Int J Mol Sci. 2025; 26(5).

PMID: 40076855 PMC: 11900591. DOI: 10.3390/ijms26052233.


Acetylated Globotetraose (Ac-Gb4) Suppresses Triple-Negative Breast Cancer Through FAK/AKT Signaling Pathway.

Lee Y, Sehar M, Botcha L, Chuang P Int J Mol Sci. 2025; 25(24.

PMID: 39769120 PMC: 11677054. DOI: 10.3390/ijms252413353.


Mechanistic and Therapeutic Implications of Protein and Lipid Sialylation in Human Diseases.

Zhong X, DAntona A, Rouse J Int J Mol Sci. 2024; 25(22).

PMID: 39596031 PMC: 11594235. DOI: 10.3390/ijms252211962.


Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer Cells.

Goode E, Orozco-Moreno M, Hodgson K, Nabilah A, Murali M, Peng Z Cancers (Basel). 2024; 16(17).

PMID: 39272811 PMC: 11393965. DOI: 10.3390/cancers16172953.


Negative Charge-Carrying Glycans Attached to Exosomes as Novel Liquid Biopsy Marker.

Kosutova N, Lorencova L, Hires M, Jane E, Orovcik L, Kollar J Sensors (Basel). 2024; 24(4).

PMID: 38400284 PMC: 10892626. DOI: 10.3390/s24041128.

References
1.
Wang J, Choi S, Niu X, Kang N, Xue H, Killam J . Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity. Int J Mol Sci. 2020; 21(21). PMC: 7664620. DOI: 10.3390/ijms21218363. View

2.
Hudak J, Canham S, Bertozzi C . Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat Chem Biol. 2013; 10(1):69-75. PMC: 3893890. DOI: 10.1038/nchembio.1388. View

3.
Triller N, Korosec P, Kern I, Kosnik M, Debeljak A . Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer. 2006; 54(2):235-40. DOI: 10.1016/j.lungcan.2006.06.019. View

4.
Miyagi T, Yamaguchi K . Mammalian sialidases: physiological and pathological roles in cellular functions. Glycobiology. 2012; 22(7):880-96. DOI: 10.1093/glycob/cws057. View

5.
Ghirardello M, Shyam R, Galan M . Reengineering of cancer cell surface charges can modulate cell migration. Chem Commun (Camb). 2022; 58(36):5522-5525. PMC: 9063860. DOI: 10.1039/d2cc00402j. View